SD Biosensor, Inc. (KRX:137310)

South Korea · Delayed Price · Currency is KRW

6,410.00

-440.00 (-6.42%)

Last updated: Oct 8, 2026, 3:00 PM KST

Market Cap	766.76B -35.6%
Revenue (ttm)	738.76B +5.2%
Net Income	-729.49B
EPS	-6,098.16
Shares Out	119.62M
PE Ratio	n/a
Forward PE	n/a
Dividend	200.00 (3.12%)
Ex-Dividend Date	Mar 30, 2026

Volume	177,932
Open	6,740.00
Previous Close	6,850.00
Day's Range	6,410.00 - 6,750.00
52-Week Range	5,800.00 - 10,190.00
Beta	0.70
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 14, 2026

About SD Biosensor

SD Biosensor, Inc., together with its subsidiaries, operates as an in-vitro diagnostic company in South Korea, India, Asia, Europe, the Americas, and Africa. The company offers STANDARD Q, which provides rapid diagnostic products; STANDARD F, a fluorescence immunodiagnostic system for various qualitative and quantitative diagnosis items; STANDARD E, an enzyme immunoassay diagnosis for large-volume tests; and STANDARD M, a field molecular diagnosis system for infectious disease diagnosis, drug resistance, and genetic testing. It also provides ST... [Read more]

Industry Medical Devices

Sector Healthcare

Founded 1999

Employees 616

Stock Exchange Korea Stock Exchange

Ticker Symbol 137310

Full Company Profile

Financial Performance

In 2025, SD Biosensor's revenue was 710.58 billion, an increase of 2.30% compared to the previous year's 694.57 billion. Losses were -512.11 billion, 420.4% more than in 2024.

Financial Statements